Background
HCM is the most common cause of sudden death in the young. The availability of ICDs over the past decade for HCM has demonstrated the potential for sudden death prevention, predominantly in adult patients.
Methods
A multicenter international registry of ICDs implanted (1987 to 2011) in 224 unrelated children and adolescents with HCM judged at high risk for sudden death was assembled. Patients received ICDs for primary (n ϭ 188) or secondary (n ϭ 36) prevention after undergoing evaluation at 22 referral and nonreferral institutions in the United States, Canada, Europe, and Australia.
Results
Defibrillators were activated appropriately to terminate ventricular tachycardia or ventricular fibrillation in 43 of 224 patients (19%) over a mean of 4.3 Ϯ 3.3 years. ICD intervention rates were 4.5% per year overall, 14.0% per year for secondary prevention after cardiac arrest, and 3.1% per year for primary prevention on the basis of risk factors (5-year cumulative probability 17%). The mean time from implantation to first appropriate discharge was 2.9 Ϯ 2.7 years (range to 8.6 years). The primary prevention discharge rate terminating ventricular tachycardia or ventricular fibrillation was the same in patients who underwent implantation for 1, 2, or Ն3 risk factors (12 of 88 [14%], 10 of 71 [14%], and 4 of 29 [14%] , respectively, p ϭ 1.00). Extreme left ventricular hypertrophy was the most common risk factor present (alone or in combination with other markers) in patients experiencing primary prevention interventions (17 of 26 [65%] ). ICD-related complications, particularly inappropriate shocks and lead malfunction, occurred in 91 patients (41%) at 17 Ϯ 5 years of age.
Conclusions
In a high-risk pediatric HCM cohort, ICD interventions terminating life-threatening ventricular tachyarrhythmias were frequent. Extreme left ventricular hypertrophy was most frequently associated with appropriate interventions. The rate of device complications adds a measure of complexity to ICD decisions in this age group. Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden death (SD) in young people, including competitive athletes (1) . Indeed, SD has been the most visible and devastating, as well as unpredictable, complication of this disease since its contemporary description Ͼ50 years ago (1, 2) . During the past decade, implantable cardioverterdefibrillators (ICD) have proved effective in preventing SD in patients with HCM, but largely in adults (3, 4) . Because there are few data focusing on pediatric patients with HCM (5) (6) (7) (8) , uncertainty persists as to the effectiveness and reliability of ICDs in this age group and See page 1536 the selection of patients who would most likely benefit from this therapy (1, 9, 10) . This consideration is most relevant to translating the risk factor model currently used in the selection of adult patients with HCM for ICDs to much younger patients (1) . Therefore, we assembled a large and novel cohort of children and adolescents with HCM and ICDs, judged at high risk for SD, to assess criteria for implantation and subsequent clinical outcomes.
Methods
Patient selection. The study group comprised 224 patients with HCM, Ͻ20 years of age, who received ICDs at 22 participating institutions in the United States, Canada, Europe, and Australia. All patients with HCM who underwent implantation for high-risk status at participating institutions from 1987 to 2011 constituted the study group. Decisions regarding ICD implantation were made at the discretion of managing pediatric cardiologists and electrophysiologists, relying largely on the risk stratification model established for the prevention of SD in patients with HCM (1,9,10).
Of 224 study patients, selected data from 24 had been included in an earlier investigation (4) but are reported herein with extended follow-up. Approval was received from institutional review boards, or the equivalent, for all participating institutions, with consent obtained from all participants. Defibrillators. Initially, single-chamber or dual-chamber ICDs were implanted with transvenous (n ϭ 185) or epicardial (n ϭ 39) lead systems with capacity for antitachycardia and antibradycardia pacing. During follow-up, all patients received updated ICDs with memory for recording and storing electrocardiographic data. Devices were implanted according to customary practice, with defibrillation thresholds tested to verify successful termination of ventricular tachyarrhythmias. Antitachycardia pacing was activated at the discretion of managing electrophysiologists. Definitions. HCM. Each patient had a clinical diagnosis of nonsyndromic HCM on the basis of 2-dimensional echocardiographic or cardiovascular magnetic resonance evidence of a hypertrophied and nondilated left ventricle in the absence of another cardiac or systemic disease that could account for the magnitude of hypertrophy evident (9 -11) . Patients with left ventricular (LV) hypertrophy (LVH) as a component of systemic disease or syndromes (e.g., Noonan syndrome, LAMP2 cardiomyopathy [Danon disease]) (12) were excluded (11) .
Maximum LV wall thickness was Ն15 mm (mean 28 Ϯ 8 mm; range: 15 to 53 mm) in 188 patients, consistent with HCM diagnosis at any age (9, 10, 13) . LV thickness was Ͻ15 mm in 36 other patients (mean 12 Ϯ 2 mm; z-score range: 2.2 to 12; mean 5 Ϯ 2) (14) . In 74 patients, extreme LVH was defined as an absolute maximal thickness Ն30 mm (mean 35 Ϯ 5 mm; range: 30 to 51 mm) (15) , in accord with prior studies (4, 9, 15) . In the 43 patients with LV thickness Ͻ30 mm (to 29 mm; mean 24 Ϯ 5 mm), the mean z-scores was 18 Ϯ 5 (range to 30).
Of the 224 patients, 172 (77%) had evidence most consistent with sarcomeric HCM, including Ն1 of the following: 1) family history of HCM (n ϭ 122, including 78 with HCM-related SD); prior surgical myectomy (n ϭ 43) or alcohol ablation (n ϭ 1) to relieve outflow obstruction; rest gradient Ն 30 mm Hg at the time of implantation (n ϭ 54); sarcomere protein mutation (n ϭ 49) (16) : MYH7 (n ϭ 23), MYBPC3 (n ϭ 8), TNNT2 (n ϭ 5); MYL2 (n ϭ 2); TPM1 (n ϭ 2); TNN13 (n ϭ 2); compound MYBPC3 (n ϭ 3); double: MYH7 and MYBPC3; MYBPC3 and TNNI3; MYH7 and CAV3; MYBC3 and ACTC1 (n ϭ 1 each).
EVENTS.
On the basis of stored electrographic analysis by expert electrophysiologists at each center, defibrillator discharges were regarded as appropriate when triggered by ventricular fibrillation (VF) or rapid ventricular tachycardia (VT) (heart rate Ͼ150 beats/min) (1, 9, 10 
FOLLOW-UP.
The duration of follow-up was computed from initial ICD implantation to first appropriate device intervention or death, whichever occurred first. In patients without appropriate ICD discharges, follow-up duration (Ն6 months) was terminated at the most recent evaluation (clinic visit or telephone contact) as of March 2012 or at heart transplantation or death. Risk factor analysis. In judging SD risk level, managing cardiologists considered the following (1,3,4,9,10,13,15, 17-19): for secondary prevention, prior cardiac arrest (with documented VF or sustained VT); and for primary prevention, 1) family history of premature HCM-related SD (n ϭ 78), 2) extreme LVH (n ϭ 117), 3) unexplained syncope inconsistent with neurocardiogenic origin (n ϭ 71), 4) nonsustained VT on 24-h ambulatory (Holter) electrocardiogram (Ն3 beats Ն120/min) (n ϭ 22), and 5) hypotensive blood pressure response to exercise (n ϭ 33). Statistical analyses. Rates of appropriate ICD discharges were calculated according to time between implantation and first appropriate intervention. Confidence intervals (CIs) were derived using the bootstrap method. Specifically, 1,000 bootstrap samples were drawn with replacement, using simple random sampling (95% CI: 2.5th to 97.5th percentiles of samples). Rates were compared among patient subgroups using chi-square tests for heterogeneity and trend or Student's t tests, as appropriate. Chi-square goodnessof-fit tests were used to assess uniformity. Cox proportional hazards analysis was used to compare ICD intervention rates. The probability of appropriate ICD intervention was estimated using the Kaplan-Meier method with subgroups compared using log-rank tests.
For continuous variables, data are expressed as mean Ϯ SD. The p values are 2-sided and considered statistically significant at Ͻ0.05. Analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, North Carolina).
Results

Baseline characteristics.
The 224 patients ranged in age from 0.1 to 19.9 years (mean 14.5 Ϯ 3.6 years) at ICD implantation for secondary (n ϭ 36) or primary (n ϭ 188) prevention ( Fig. 1 , Table 1 ). Of these patients, 134 (60%) were Յ15 years of age; 151 (67%) were male. The mean follow-up period was 4.3 Ϯ 3.3 years (range to 17 years). Appropriate ICD interventions. ALL PATIENTS. Of 224 study patients, 43 (19%) experienced Ն1 appropriate ICD intervention immediately restoring sinus rhythm by terminating VF (n ϭ 21) or VT (n ϭ 22) (Figs. 2 to 5). Initial ICD activations were defibrillation shocks in 40 patients and overdrive antitachycardia pacing in 3. The appropriate intervention rate for the overall study group was 4.5% per year (95% CI: 3.3% to 6.0%).
Patients with appropriate discharges underwent initial implantation at 13.5 Ϯ 3.6 years of age (range: 4 to 19 years) and experienced first intervention at 16.4 Ϯ 4.8 years (range: 5 to 26 years). Cumulative 5-year probability of discharge was 17%.
SECONDARY PREVENTION. Thirty-six study patients received ICDs after resuscitated cardiac arrest or sustained VT; 17 (47%) experienced appropriate discharges at ages 5 to 26 years (mean 15.6 Ϯ 6.4 years; at 14.0% per year; 95% CI: 7.7% to 22.7%). Cumulative 5-year probability of discharge was 43%. Of these 17 patients, 15 had no or only mild heart failure symptoms.
PRIMARY PREVENTION. Appropriate interventions occurred in 26 of 188 patients (14%) judged at increased risk for SD solely on the basis of risk markers. Initial events occurred at ages 9 to 23 years (mean 17.0 Ϯ 3.4 years; at 3.1% per year; 95% CI: 2.0 to 4.4). Cumulative 5-year probability of discharge was 12%. Of these 26 patients, 22 had no or only mild heart failure symptoms. The rate of ICD intervention for secondary prevention exceeded that for primary prevention 4-fold (hazard ratio: 4.1; 95% CI: 2.2 to 7.5; p Ͻ 0.001) (Fig. 3) .
Patients with appropriate interventions (n ϭ 26) had greater magnitude of LVH than patients without interventions (n ϭ 162) (30 Ϯ 11 mm vs. 25 Ϯ 9 mm, respectively, p ϭ 0.026). Of the 43 patients who underwent surgical myectomy, 2 (5%) incurred appropriate interventions a mean of 0.2 Ϯ 5.3 years later (rate 1% per year). Timing and multiple shocks. Time between implantation and first appropriate ICD intervention ranged from 1 day to 8.6 years (mean 2.9 Ϯ 2.7 years; Ն5 years in 13 patients [30%]) (Fig. 4) . Twenty-five study patients received Ն2 total therapies (range to 7), including 13 who underwent implantation for primary and 12 for secondary prevention. ICD storms (Ն2 shocks in 24 h) were reported in 8 others. Twenty-seven of 43 appropriate interventions occurred in the initial 30 months after implantation, including 12 (44%) in patients with ICDs implanted for secondary prevention or with end-stage systolic dysfunction. history of SD, and 3 of 13 (23%) with syncope; 2 other implants were for nonconventional indications (Table 2) . Complications. Sixty-three patients (28%; 6.5% per year) experienced inappropriate ICD shocks due to sinus tachycardia (n ϭ 30), supraventricular tachycardia (n ϭ 12), T-wave oversensing (n ϭ 12), lead malfunction (n ϭ 7), or electrical interference (n ϭ 2 Maron et al. April 9, 2013 April 9, :1527 Sudden Death Prevention in Children With HCM (p ϭ 0.61). Notably, of 63 patients experiencing inappropriate shocks, 19 (30%) also had appropriate interventions. An additional 28 study patients (12%) had complications regarded as particularly significant: lead fracture, dislodgement, or insulation failure without inappropriate shocks (n ϭ 15); infection (n ϭ 2); hemorrhage or thrombosis (n ϭ 4); generator malfunction (n ϭ 4); and right ventricular perforation, lacerated coronary vein, or exploratory sternotomy (n ϭ 1 each). Therefore, 91 patients (40%) experienced Ն1 device-related complication (9.5% per year) at a mean age of 17 Ϯ 5 years.
Discussion
The prevention of SD is a major aspiration for the HCM population (1, 3, 4) . Over the past decade, studies documenting the frequency of ICD interventions terminating potentially lethal tachyarrhythmias, largely in adult patients undergoing implantation for high-risk status, have reported the lifesaving potential of this contemporary therapy (3, 4, 8, (22) (23) (24) (25) (26) . Indeed, ICDs have changed the natural history of HCM for many patients and remain the only treatment strategy that prolongs life in patients with this disease. In our previous large, primarily adult registry (3, 4) , patients who underwent implantation at an average age of 42 years had a 5% per year intervention rate (primary prevention 4% per year). These favorable results have been replicated in several smaller series reporting virtually identical discharge rates (8, (22) (23) (24) (25) (26) .
Although ICD experience in HCM has been predominantly in adult patients, SD has an important predilection for younger patients (27) . To clarify the role of ICD therapy in children and adolescents, we assembled the present unique multicenter international cohort of high-risk patients with HCM who underwent implantation at Ͻ20 years of age. In this study of Ͼ200 pediatric patients, ICDs proved effective in aborting life-threatening VT or VF in almost 20% (about 90% of these with no or only mild symptoms).
The secondary prevention annual intervention rate was 13% for those patients surviving cardiac arrest and about 3% for primary prevention on the basis of risk factors, and similar to rates previously reported for high-risk adult patients with HCM (1,3,4) . When extrapolated, this rate predicts a substantial ICD intervention rate over the many ICD Intervention Rates
Cumulative rates for first appropriate implantable cardioverter-defibrillator (ICD) intervention, shown separately for patients who underwent implantation for primary (n ϭ 188) or secondary (n ϭ 36) prevention. The rate of first appropriate ICD shock for secondary prevention exceeded that for primary prevention by 4-fold.
Figure 4 Unpredictability of Arrhythmogenic Substrate in Patients With Hypertrophic Cardiomyopathy
Time intervals from implantable cardioverter-defibrillator (ICD) implantation to first appropriate intervention in 224 patients.
Figure 5 Number of Sudden Death Risk Factors and ICD Interventions
Cumulative rates for first appropriate implantable cardioverter-defibrillator (ICD) intervention in 188 patients who underwent implantation for primary prevention and 1, 2, or Ն3 risk markers. Event distribution was nonuniform during the follow-up period, with early interventions disproportionate (p ϭ 0.023).
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years that these young patients will continue to be at risk. Indeed, the interval from implantation to first device activation can be considerable, up to 10 years in adults (1, 3, 4, 22) , and possibly even longer. In the present study, time from implantation to first appropriate discharge was up to 8 years and Ն5 years in about one-third of patients.
There is virtually no disagreement regarding the appropriateness of ICD therapy after cardiac arrest (secondary prevention) (1,3,9,10). The major issue influencing ICD decision making in children and adolescents is patient selection for primary prevention. Our data on the number of risk factors required to justify implant consideration proved consistent with the experience in adult patients (1,3,4,10,22) . Specifically, we could not identify a significant difference in the likelihood of appropriate ICD discharges among patients who underwent implantation for 1, 2, or Ն3 conventional risk markers. That almost 50% of appropriate interventions were in patients with only 1 risk factor substantiates the principle that a single major marker within the clinical profile of an individual patient may be sufficient to consider a prophylactic ICD (1, 3, 4, 22) .
In this cohort, extreme LVH was the risk marker most commonly associated (either alone or in combination with other markers) with future ICD interventions i.e., extreme LVH was present in about two-thirds of patients experiencing appropriate discharges for primary prevention. This observation is consistent with the recognition that massive degrees of LVH were an important SD risk factor for patients with HCM in the pre-ICD era (13) .
Furthermore, in this and other studies, ICDs proved effective in terminating VT and VF despite substantially increased LV mass and/or LV outflow obstruction with high intraventricular pressures. Notably, 4 of our 5 patients in whom extreme LVH was the sole risk factor promoting the implantation of prophylactic ICDs had LV wall thicknesses Ն30 mm, suggesting that the absolute 30-mm cutoff for high risk may be relevant to HCM children and adolescents independent of body size, similar to the circumstance in adults (13) .
It was not possible to apply a Cox proportional hazards regression analysis to assess the relative strength of individual risk factors for ICD interventions because of insufficient power (maximum 0.1), given our relatively low event rate. Notably, ambulatory nonsustained VT (the only SD marker that directly measures arrhythmia burden in HCM) was uncommonly associated with events, in contrast to the HCM population data of Monserrat et al. (28) . As a sole risk marker, the hypotensive blood pressure response to exercise is often problematic and is rarely the sole basis for primary prevention ICD decisions, given that it can be triggered by dynamic outflow obstruction and is potentially reversible by surgical myectomy (11) .
At this early juncture, it is uncertain whether ICDs offer such very young, high-risk patients an opportunity to achieve normal or near-normal longevity, given the recognized unpredictability and complexity of this disease (1,3,4,22,29) . However, notably, ICDs failed to abort an SD event in only 1 study patient, a high-risk 21-year-old male patient with preserved systolic function who died because his mechanically defective ICD (known only to the manufacturer) failed to deliver a defibrillation shock because of massive electrical overstress and short circuiting (21) . Patients were entered into the present cohort because they were judged to be at high risk for SD by their managing cardiologists. Therefore, our observations are confined to a particular subset of patients that may not be entirely representative of the general HCM population of this age, for which the vast majority do not experience life-threatening events. Indeed, 25% of our patients experienced early-onset aggressive disease (including heart transplantation), which in principle overwhelmed the potential benefit of ICD implantation.
The importance of device-related complications cannot be underestimated or overstated in this young patient cohort. A significant minority of patients experienced adverse ICD consequences, including lead malfunction (sometimes due to manufacturing defects), inappropriate shocks, and other more substantial complications. In particular, lead systems continue to constitute the "weakest link" in the ICD system and may not be designed to remain intact and perform effectively over the very long periods required for young patients and HCM and decades of productive life ahead (30) . Therefore, ICD decisions in children inevitably require weighing anticipated benefit for SD prevention and the preservation of life against possible device complications, requirement for multiple generator changes, the possible psychological burden imposed by ICDs, and some quality-of-life restrictions (31) . Indeed, the complication rate (including inappropriate shocks) was 3-fold higher than appropriate interventions for VT or VF (9% vs. 3%). However, importantly, about 30% of patients with device complications also had appropriate lifesaving ICD interventions.
These considerations can create unique management dilemmas in pediatric cardiology, particularly when decisions regarding prophylactic implants involve ambiguous risk-factor assessment. Indeed, the paradox emerges in which healthy-appearing children and adolescents in the age range of greatest SD predilection (27) are also those most likely to experience device complications, given their youth and level of physical activity.
Whether subcutaneous defibrillators, largely untested in HCM, will ultimately prove as efficacious as transvenous systems is not yet known (32, 33) . However, at present, caution is warranted in considering subcutaneous defibrillators in this young patient population (33) . Single-chamber ICDs still represent the most appropriate option for young high-risk patients with HCM, given the lower potential for lead complications than is expected with dual-chamber devices (34) .
The disproportionate occurrence of relatively early defibrillation shocks suggests the theoretical possibility of leadrelated proarrhythmia (35) , rather than beneficial diseaserelated interventions. However, in this study, as in our registry of adult patients with HCM (36), a substantial proportion of early ICD discharges could be explained by a subset of patients particularly prone to subsequent VT or VF because they underwent implantation after cardiac arrest or with systolic dysfunction. In addition, it is theoretically possible that some defibrillator shocks considered to be appropriate therapy could have been triggered by ventricular tachyarrhythmias that may have self-terminated (i.e., if the device had not been present), similar to the situation that has been proposed for implanted patients with ischemic heart disease (37, 38) . However, whether the principle in coronary artery disease that ICD interventions for VT overestimate appropriate device therapy (and SD rates) should be applied directly to HCM is presently unresolved.
Our registry study design was unavoidable, given the impracticality of prospective and/or randomized ICD trials in HCM, particularly in this age group. Obstacles to randomization include the infrequency of clinically identified patients with HCM in pediatric cardiology practice, the relatively low event rate dispersed over many decades, and ethical considerations whereby some patients would be excluded from potentially lifesaving therapy. Therefore, the selection of patients for ICDs was based on current riskfactor models (1) and practice patterns instituted at each participating center, with decision-making consistent with the available consensus recommendations in the vast majority of patients (3, 4, 9, 10, 22) .
Conclusions
Data from this large, international, multicenter cohort are relevant to patient management and ICD decision making in young high-risk patients with HCM. Our findings support the current risk stratification strategy for identifying patients with HCM susceptible to life-threatening ventricular tachyarrhythmias, and underscore an important role for SD prevention (with ICDs) in children and adolescents. These data also emphasize the importance of balancing considerations for the preservation of life using ICDs against the possibility of device-related complications that may be anticipated with implantation so early in life.
